ADS-ADEA 2015*
Chairs: Jeff Flack & Tang Wong
LY2963016 Insulin Glargine (LY IGlar) Compared with Lantus® Insulin Glargine (IGlar) in Patients with Type 2 Diabetes Mellitus (T2DM): Efficacy, Safety, and Patient-reported Outcomes from the ELEMENT-2 Study (#164)
3:30 PM
Age, BMI and Diabetes Duration: Effect on Glycaemic Control and Hypoglycaemia with Insulin Glargine 300 U/mL in Type 2 Diabetes (#165)
3:45 PM
Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM: The GetGoal-Duo2 Evidence-Based Trial (NCT01768559) (#166)
4:00 PM
Characteristics Associated With Greater A1C Response to Exenatide Twice Daily at 6 Months (#167)
4:15 PM
Effects of exenatide on the blood pressure and heart rate responses to intraduodenal glucose in type 2 diabetes (#168)
4:30 PM
Effect of Empagliflozin Compared with Glimepiride as Add-on to Metformin for 2 Years on the Amount and Distribution of Body Fat in Patients with Type 2 Diabetes (T2DM) (#169)
4:45 PM
Diabetic Ketoacidosis (DKA) associated with SGLT2i use in T2DM – First case reports in Australia. (#170)
5:00 PM
10-year trends in glycaemic control, chronic kidney disease and use of diabetic medication in patients with type 2 diabetes (T2DM) - an Australian DINGO (Diabetes Informatics Group) multicentre study of over 11,000 patients seen in private endocrine practice (#171)
5:15 PM